Characterization of Altered Waking States of Consciousness in Healthy Humans
NCT03853577 · University of Zurich
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Assessment of change of the 'perturbational complexity index' (PCI) in psilocybin compared to placebo condition in healthy humans as indexed by TMS/EEG respones
Measured over First investigational visit at week 1, second investigational visit at week 3
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
1 study site
| Facility | City | Region | Country |
|---|---|---|---|
| Psychiatrische Universitätsklinik Zürich | Zurich | — | Switzerland |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT03853577 on ClinicalTrials.gov →
Last updated in the registry 2021-04-29. Registry records change; this page reflects the data build of 2026-08-25.
Related